NCT04487431View on ClinicalTrials.gov

A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

February 11, 2021

Conditions
Endometriosis Related PainOveractive BladderDiabetic Neuropathic PainRefractory or Unexplained Chronic Cough
Interventions
DRUG

BAY1817080

Oral single dose

DRUG

[14C]BAY1817080

Oral single dose

Trial Locations (1)

9728 NZ

PRAHealthSciences, Groningen

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04487431 - A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B) | Biotech Hunter | Biotech Hunter